Selinexor

Extended indication	Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Selinexor
Domain	Oncology and Hematology
Reason of inclusion	Indication extension
Main indication	Multiple Myeloma
Extended indication	Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Proprietary name	Nexpovio
Manufacturer	Karyopharm
Mechanism of action	Other
Route of administration	Oral
Therapeutical formulation	Coated tablet
Budgetting framework	Intermural (MSZ)
Additional remarks	CRM1 nuclear export inhibitor.

Registration route	Centralised (EMA)
Type of trajectory	Normal trajectory
ATMP	No
Submission date	May 2021
Expected Registration	March 2022
Orphan drug	Yes
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.